|
|
||||||||
1+TCR
+ and V
2+TCR
+ T Lymphocytes from Healthy Donors and Multiple Sclerosis Patients: Involvement of Phosphatidylinositol 3 Kinase and Calcium Calmodulin-Dependent Kinase II1








* Laboratory of Immunology, National Institute for Cancer Research, Genoa, Italy;
Laboratory of Tumor Immunology, Scientific Institute San Raffaele, Milan, Italy;
Laboratory of Neuroimmunology, IRCCS Santa Lucia Foundation,
Department of Neurosciences "Lancisi," Ospedale San Camillo, and
¶ Department of Neurosciences, University of Tor Vergata, Rome, Italy
We have previously reported that the
V
2+TCR
+ T lymphocyte subset,
expressing the NK receptor protein 1a (NKRP1a; CD161), is expanded in
patients with relapsing-remitting multiple sclerosis and uses this
molecule to migrate through endothelium. In this work, we show that
V
1+ and V
2+ 
T lymphocytes use
distinct signal transduction pathways to accomplish this function.
Indeed, we have found that V
1+ cells lack NKRP1a and
selectively express the platelet endothelial cell adhesion molecule 1
(PECAM1; CD31), which drives transendothelial migration of this cell
subset, at variance with V
2+ T cells, which are PECAM1
negative and use NKRP1a for transmigration. Interestingly, when
V
2+ T cells were pretreated with two specific inhibitors
of the calcium calmodulin-dependent kinase II KN62 and KN93, but not
with the inactive compound KN92, the number of migrating cells and the
rate of transmigration were significantly decreased. In turn, the
phosphatidylinositol 3 kinase blockers wortmannin and LY294002 exerted
a dose-dependent inhibition of V
1+ cell migration.
Finally, NKRP1a and PECAM1 engagement led to activation of different
signal transduction pathways: indeed, oligomerization of NKRP1a on
V
2+ T cells activates calcium calmodulin-dependent
kinase II, while occupancy of PECAM1 on V
1+ cells
triggers the phosphatidylinositol 3 kinase-dependent Akt/protein kinase
B
activation. These findings suggest that subsets of 
T
lymphocytes may migrate to the site of lesion in multiple sclerosis
using two different signaling pathways to
extravasate.
This article has been cited by other articles:
![]() |
M. Nakhaei-Nejad, A. M. Hussain, Q.-X. Zhang, and A. G. Murray Endothelial PI 3-kinase activity regulates lymphocyte diapedesis Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3608 - H3616. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. POGGI, M. ZANCOLLI, S. CATELLANI, G. BORSELLINO, L. BATTISTINI, and M.R. ZOCCHI Migratory Pathways of {gamma}{delta} T Cells and Response to CXCR3 and CXCR4 Ligands: Adhesion Molecules Involved and Implications for Multiple Sclerosis Pathogenesis Ann. N.Y. Acad. Sci., June 1, 2007; 1107(1): 68 - 78. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sicard, S. Ingoure, B. Luciani, C. Serraz, J.-J. Fournie, M. Bonneville, J. Tiollier, and F. Romagne In Vivo Immunomanipulation of V{gamma}9V{delta}2 T Cells with a Synthetic Phosphoantigen in a Preclinical Nonhuman Primate Model J. Immunol., October 15, 2005; 175(8): 5471 - 5480. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Eberl, R. Engel, S. Aberle, P. Fisch, H. Jomaa, and H. Pircher Human V{gamma}9/V{delta}2 effector memory T cells express the killer cell lectin-like receptor G1 (KLRG1) J. Leukoc. Biol., January 1, 2005; 77(1): 67 - 70. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Poggi, C. Venturino, S. Catellani, M. Clavio, M. Miglino, M. Gobbi, A. Steinle, P. Ghia, S. Stella, F. Caligaris-Cappio, et al. V{delta}1 T Lymphocytes from B-CLL Patients Recognize ULBP3 Expressed on Leukemic B Cells and Up-Regulated by Trans-Retinoic Acid Cancer Res., December 15, 2004; 64(24): 9172 - 9179. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Poggi, R. Carosio, D. Fenoglio, S. Brenci, G. Murdaca, M. Setti, F. Indiveri, S. Scabini, E. Ferrero, and M. R. Zocchi Migration of V{delta}1 and V{delta}2 T cells in response to CXCR3 and CXCR4 ligands in healthy donors and HIV-1-infected patients: competition by HIV-1 Tat Blood, March 15, 2004; 103(6): 2205 - 2213. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |